ASCT

PROCEDURE12 trials

Sponsors

Fondazione Italiana Linfomi - ETS, Lymphoma Study Association, City of Hope Medical Center, Peking University People's Hospital, AHS Cancer Control Alberta

Conditions

Diffuse Large B-Cell LymphomaExtramedullary Multiple MyelomaFollicular LymphomaHodgkin's Lymphoma - Relapsed/RefractoryIPI≥2LymphomaLymphoma, Large Cell, DiffuseMultiple Myeloma

Phase 1

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

TerminatedNCT02295722

AHS Cancer Control AlbertaFollicular Lymphoma, Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive

Start: 2015-04-30End: 2023-02-28Updated: 2024-07-08

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

CompletedNCT02655458

Hearn Jay ChoMultiple Myeloma

Start: 2016-01-31End: 2017-07-13Updated: 2017-08-18

Phase 2

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

CompletedNCT00689169

Lymphoma Study AssociationLymphoma, Large Cell, Diffuse

Start: 2007-08-31End: 2014-01-31Updated: 2018-03-07

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

CompletedNCT00695409

City of Hope Medical CenterLymphoma

Start: 2008-03-18End: 2017-03-27Updated: 2018-07-06

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruitingNCT03004287

University of ArkansasMultiple Myeloma

Start: 2017-07-01End: 2027-10-31Target: 50Updated: 2025-09-10

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

RecruitingNCT06140966

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyExtramedullary Multiple Myeloma, Multiple Myeloma, Primary Plasma Cell Leukemia

Start: 2023-10-20End: 2027-10-20Target: 54Updated: 2025-04-16

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

RecruitingNCT06793449

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2025-02-05End: 2030-12-31Target: 80Updated: 2025-08-03

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

Not yet recruitingNCT07070934

Xuzhou Medical UniversityMultiple Myeloma, Newly Diagnosed

Start: 2025-07-15End: 2028-07-31Target: 60Updated: 2025-07-17

Phase 3

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Fondazione Italiana Linfomi - ETSDiffuse Large B-Cell Lymphoma, IPI≥2

Start: 2006-01-31End: 2013-09-30Target: 399Updated: 2011-02-15

MInimal Residual Disease Adapted Strategy

Active, not recruitingNCT04934475

Intergroupe Francophone du MyelomeMultiple Myeloma

Start: 2021-12-08End: 2028-09-30Updated: 2024-11-07

Phase 4

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Peking University People's HospitalMultiple Myeloma

Start: 2013-05-31End: 2017-05-31Target: 50Updated: 2013-06-06

Unknown Phase

Allo-HSCT vs ASCT in Adult T-LBL

Not yet recruitingNCT06741813

Peking University People's HospitalT Lymphoblastic Lymphoma

Start: 2025-01-01End: 2029-12-31Target: 230Updated: 2024-12-19

Related Papers

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Blood2025-11-03

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Blood2025-11-03

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

2025-07-019 citations

Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma

New England Journal of Medicine2025-06-0329 citations

MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.

Journal of Clinical Oncology2025-05-282 citations

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

Blood Advances2024-11-226 citations

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Journal for ImmunoTherapy of Cancer2024-04-015 citations

Prognostic impact of <i>TP53</i> mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial

British Journal of Haematology2021-12-2331 citations

A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma

Haematologica2020-08-1311 citations

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

2017-06-2899 citations

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma

Biology of Blood and Marrow Transplantation2014-07-2614 citations